| Risk factors for development of cholestatic drug-induced liver injury: inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4 K Köck, BC Ferslew, I Netterberg, K Yang, TJ Urban, PW Swaan, ... Drug metabolism and disposition 42 (4), 665-674, 2014 | 168 | 2014 |
| A PK/PD analysis of circulating biomarkers and their relationship to tumor response in atezolizumab‐treated non‐small cell lung cancer patients I Netterberg, CC Li, L Molinero, N Budha, S Sukumaran, M Stroh, ... Clinical Pharmacology & Therapeutics 105 (2), 486-495, 2019 | 31 | 2019 |
| Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring I Netterberg, EI Nielsen, LE Friberg, MO Karlsson Cancer Chemotherapy and Pharmacology 80, 343-353, 2017 | 28 | 2017 |
| The risk of febrile neutropenia in breast cancer patients following adjuvant chemotherapy is predicted by the time course of interleukin‐6 and C‐reactive protein by modelling I Netterberg, MO Karlsson, EI Nielsen, AL Quartino, H Lindman, ... British Journal of Clinical Pharmacology 84 (3), 490-500, 2018 | 14 | 2018 |
| Inhibition of the hepatic basolateral bile acid transporter MRP4 predicts cholestatic drug-induced liver injury (DILI): LB-22 K Köck, BC Ferslew, I Netterberg, K Yang, TJ Urban, PW Stewart, ... Hepatology 56 (6), 1530A, 2012 | 4 | 2012 |
